Browse the evidence

GLP-1 receptor agonists (semaglutide 2.4 mg/week and liraglutide 3 mg/day) produce significant weight loss in adults with obesity or overweight with comorbidities by delaying gastric emptying and increasing satiety, with semaglutide demonstrating superior efficacy compared to liraglutide.

If you have obesity or overweight with a related health condition, ask your doctor about GLP-1 agonists like semaglutide. They are taken as a once-weekly injection and work by making you feel full and slowing digestion. They are most effective when combined with a reduced-calorie diet and increased physical activity.

Intentional weight loss in older adults using anti-obesity medicines (AOMs) improves cardiometabolic outcomes and preserves skeletal muscle strength and bone mineral density, countering the risks of sarcopenia and functional decline.

If you are over 60 and have obesity, intentional weight loss using FDA-approved medications (like semaglutide or tirzepatide) combined with resistance training is safe and effective. It improves heart and metabolic health without necessarily causing frailty, provided you work with a clinician to manage side effects and maintain muscle mass.

Post-ACL reconstruction rehabilitation using Blood Flow Restriction (BFR) with low-load resistance training (30% 1RM) produces significantly greater gains in quadriceps and hamstring muscle strength and knee physical function compared to high-load resistance training (70% 1RM) without occlusion.

If you are in early rehab after ACL surgery, ask your physical therapist about Blood Flow Restriction (BFR) training. It allows you to use light weights (30% of your max) while still getting strong muscle gains, which is safer for your graft than heavy lifting. This method also helps reduce pain and improves knee function faster than standard heavy lifting in the first 3 months.

GLP-1 receptor agonists (GLP1RAs) produce significant weight loss and glycemic control in type 2 diabetes and obesity, with efficacy varying by specific agent, dose, and formulation.

If you have obesity or type 2 diabetes, GLP-1 drugs like semaglutide can help you lose significant weight and control blood sugar. You take it once a week. Side effects like nausea are common at first but usually go away. It works best when combined with healthy eating and exercise.

Soy protein supplementation reduces exercise-induced metabolic biomarkers such as triglycerides, uric acid, and lactate, and improves antioxidant status compared to whey protein in long-term studies.

Soy protein is not just about muscle; it actively helps your body handle oxidative stress and metabolic strain from exercise. It reduces lactate, uric acid, and triglycerides more effectively than some other sources. This makes it a smart choice for overall metabolic health alongside muscle building.

Both high-intensity (recording all dietary intake) and low-intensity (recording specific dietary components) self-monitoring strategies are effective in supporting statistically significant weight loss in behavioral interventions for adults with overweight or obesity.

You can lose weight by tracking your diet, and you don't have to track every single calorie to see results. You can choose to track all your food (high intensity) or just specific items like sugary drinks or snacks (low intensity). Both approaches have been shown to produce significant weight loss compared to no intervention. The key is consistency and using the method that you can sustain, whether that is a paper log, an app, or a phone call.

A multi-channel, information technology-enabled health promotion intervention significantly reduces daily intake of fat, sugar, and salt while increasing fruit and vegetable consumption in urban adults.

Adopt a multi-channel approach to dietary improvement. Use technology (SMS, apps) for reminders and education, but pair it with tangible tools like measuring spoons and visual guides (e.g., a table mat) to make tracking fat, sugar, and salt intake easier. This combination was shown to significantly improve diet quality over six months in diverse urban populations.

The same multi-channel IT-enabled dietary intervention leads to significant improvements in secondary health biomarkers, including reduced BMI, diastolic blood pressure, fasting plasma glucose, and triglycerides.

Improving diet quality through structured, tech-supported interventions can yield measurable metabolic benefits, including lower blood pressure, blood sugar, and triglycerides, even without explicit exercise prescriptions.

Higher adherence to the Food Compass nutrient profiling system, measured by an individual's Food Compass Score (i.FCS), is associated with lower all-cause mortality, improved cardiometabolic risk factors, and lower prevalence of chronic diseases in U.S. adults.

Focus on eating foods with higher Food Compass scores, which prioritize nutrient density, healthy fats, fiber, and whole ingredients while minimizing additives and ultra-processing. This dietary pattern is linked to lower risks of heart disease, diabetes, cancer, and early death. You don't need to track every nutrient; choosing foods rated highly by this system generally leads to better health outcomes.

Triple agonist retatrutide (GLP-1/GIP/glucagon) produces superior weight loss (up to 24.2% at 12mg) compared to dual agonists and GLP-1 monotherapy, driven by synergistic activation of all three receptors.

Retatrutide, a once-weekly injection targeting three gut hormones, has shown unprecedented weight loss (up to 24%) in clinical trials for obesity. While effective, it carries a risk of gastrointestinal side effects like nausea, which are usually manageable by starting at a low dose and increasing slowly. It represents a significant advancement over older GLP-1 drugs.

Intentional weight loss, particularly when sustained, reduces the incidence of obesity-related cancers, with even modest losses (2-4.5 kg) showing significant risk reduction.

You do not need to reach a 'perfect' weight to lower your cancer risk. Sustained, modest weight loss (even just 2-4.5 kg) significantly reduces the risk of breast cancer in postmenopausal women. Focus on maintaining this loss through sustainable dietary and activity changes rather than extreme measures.

Sustained intentional weight loss of >10–15 kg through dietary intervention can induce remission of type 2 diabetes (HbA1c <48 mmol/mol without medication) by reducing ectopic fat in the liver and pancreas and restoring beta cell function.

To potentially reverse type 2 diabetes, you need to lose a significant amount of weight (more than 10-15 kg) and keep it off. This isn't just about lowering blood sugar with drugs; it's about removing fat from your liver and pancreas so your body can regulate blood sugar naturally again. This is most likely to work if you have had diabetes for a short time. You should seek a structured, professionally supported dietary program rather than relying solely on medication.

Supplementing with β-Hydroxy-β-Methylbutyrate (HMB) or Leucine provides equivalent hypertrophy and strength gains to a control group when combined with resistance training in men.

If you are a resistance-trained man, taking HMB (3g/day) or Leucine (6g/day) will not give you better muscle or strength gains than just doing your training and eating normally. You do not need to buy these specific supplements for enhanced results.

Brief, vigorous high-intensity interval stair climbing (STAIR) improves cardiorespiratory fitness (VO2peak) in patients with coronary artery disease (CAD) to a degree equivalent to traditional moderate-intensity continuous training (TRAD), while requiring significantly less total exercise time.

If you have coronary artery disease, you can improve your heart fitness by climbing stairs vigorously for short bursts, rather than walking for long periods. Try climbing 12 stairs up and down, resting for 90 seconds, and repeating this 3 times. Do this 3 times a week. This takes about 7 minutes of actual exercise (plus warm-up/cool-down) and has been shown to improve heart fitness just as much as 30+ minutes of moderate walking, without increasing risk.

Tirzepatide significantly reduces ad libitum energy intake and body weight in adults with overweight or obesity, primarily by decreasing fasting appetite, food cravings, and disinhibition rather than increasing cognitive restraint.

Tirzepatide, a once-weekly injectable medication, significantly reduces food intake and body weight in adults with overweight or obesity. It works by lowering appetite, reducing food cravings, and decreasing the tendency to overeat, rather than by increasing willpower or cognitive restraint. While gastrointestinal side effects like nausea are common, they are often mild and tend to occur more frequently after the first injection. This suggests that tirzepatide can be an effective tool for managing energy intake and promoting weight loss, particularly for those who struggle with appetite and cravings.

Objective dietary assessment methods, such as biomarkers of food intake (BFIs) and image-based assessment, are superior to subjective methods (like 24-hour recalls) for monitoring dietary intake and improving adherence in obesity management.

To get the most out of your diet plan, use objective tools to track what you eat. Instead of relying on memory, which can be inaccurate, use apps that take photos of your meals or, if available, biomarker tests (like urine or blood tests) to verify your intake. This reduces guesswork and helps you stay on track with your personalized nutrition plan.

Lifestyle interventions (caloric restriction, physical activity, behavioral changes) are critical components for obesity management, with a target of 5-10% weight loss over 6 months being an appropriate initial goal.

Start with a daily caloric deficit of 500 kcal and aim for 150-300 minutes of moderate exercise per week plus strength training twice a week. Your initial goal should be 5-10% weight loss over 6 months. Focus on building sustainable habits rather than extreme diets.

Ingestion of 20–30 g of leucine-rich protein stimulates skeletal muscle protein synthesis and activates the mTORC1 pathway within 2 hours, an effect potentiated by prior resistance exercise.

To maximize muscle growth, consume 20–30 grams of high-quality protein (like meat, eggs, or dairy) per meal. This amount is sufficient to trigger your muscles' growth machinery (mTORC1). Doing this after resistance exercise helps, but you don't need massive amounts of extra protein beyond this threshold for each meal.

High-protein diets (above 25-30% energy) promote satiety and reduce fat mass without affecting lean mass, primarily through hormonal signaling (low ghrelin, high leptin) and reduced reward sensitivity.

To lose fat while keeping muscle, aim for a diet where 25-30% or more of your calories come from protein. This helps you feel full, reduces hunger hormones, and lowers your sensitivity to food rewards, making it easier to stick to a calorie deficit.

High dietary fiber intake promotes gut microbiota diversity and short-chain fatty acid generation, which decreases inflammation and supports gut barrier integrity, thereby reducing type 2 diabetes risk.

Eat more minimally processed plant foods like whole grains, vegetables, fruits, legumes, nuts, and seeds. This increases gut bacteria diversity and produces beneficial compounds (SCFAs) that reduce inflammation and protect your gut barrier, lowering your risk of type 2 diabetes. Note that individual responses vary based on your current gut bacteria.

Rest-pause training elicits superior strength adaptations compared to traditional resistance training when total training volume is equalized.

If you want to maximize strength, use rest-pause sets. Perform your main lifts at 75% of your one-rep max, but instead of resting between sets, take short 10-20 second breaks within the set to complete your target reps. This method generates more strength than doing the same total number of reps with standard rest periods.

GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, and tirzepatide) significantly reduce hepatic lipid content and improve liver histology (steatosis, inflammation, and fibrosis) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), primarily through weight loss and direct metabolic modulation.

If you have fatty liver disease (MASLD) and struggle with weight or blood sugar, GLP-1 medications like semaglutide or tirzepatide are highly effective treatments. They don't just help you lose weight; they directly reduce fat in the liver and can reverse inflammation and early scarring. While they are injections and may cause temporary stomach upset, the clinical data shows they significantly improve liver health outcomes compared to placebo.

Intensive lifestyle modification (diet and exercise) reduces cardiovascular risk in Type 2 Diabetes patients, but long-term maintenance of weight loss is difficult, and significant risk reduction is only seen in those who maintain >10% weight loss.

Losing weight through diet and exercise is one of the best things you can do for your heart if you have Type 2 Diabetes. However, it is hard to keep the weight off. If you can lose and keep off more than 10% of your body weight, your risk of heart problems drops significantly. Even if you can't maintain that much weight loss, any improvement in your diet and activity level is beneficial. Don't be discouraged if you regain some weight; focus on making sustainable changes.

A multidisciplinary intensive lifestyle intervention (nutrition, exercise, behavioral therapy, and medication adjustment) sustains significant weight loss (approx. 6.4%) and improves cardiovascular risk factors in patients with Type 2 Diabetes and obesity for up to 5 years in real-world clinical settings.

For T2D patients, do not rely on diet or exercise alone. Engage a team (dietitian, exercise physiologist, psychologist). Start with a structured, hypocaloric meal plan (1200-1800 kcal) and progressive exercise (up to 300 min/week). Crucially, work with your doctor to switch weight-gaining diabetes meds (like insulin or sulfonylureas) to weight-neutral or weight-loss agents (like GLP-1s or SGLT-2s) to facilitate sustainable loss.